67Cu-SAR-bisPSMA

· Clarity Pharmaceuticals Ltd

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for 67Cu-SAR-bisPSMA, covering 2026-02-05 to 2026-02-05. Get the full timeline:

Most recent: Clinical Trial Update: 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) [Phase 1, Phase 2]

See pricing